Survival in Lymph Node Negative Adenocarcinoma of the Esophagus after R0 Resection With and Without Neoadjuvant Therapy: Evidence for Downstaging of N Status

Leers, Jessica M.; Ayazi, Shahin; Hagen, Jeffrey A.; Terterov, Sergei; Klipfel, Nancy; Oezcelik, Arzu; Abate, Emmanuele; Lipham, John C.; DeMeester, Steven R.; Banki, Farzaneh; DeMeester, Tom R.

doi:10.1016/j.jamcollsurg.2009.01.017

Cited by 18 publications

(10 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Investigators have reported that although neoadjuvant therapy may eradicate lymph node metastases, it does not result in the same outcomes as those achieved in patients with N0 disease treated with surgery alone. The poor clinical outcomes observed in N0 patients after neoadjuvant therapy suggest that they initially had nodal involvement and were downstaged by eradication of lymph node disease 23.…”

Section: Discussionmentioning

confidence: 99%

Esophageal cancer—the five year survivors

Kim

Grobmyer

Smith

et al. 2010

Journal of Surgical Oncology

103

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Esophageal cancer—the five year survivors

Kim

Grobmyer

Smith

et al. 2010

Journal of Surgical Oncology

103

View full text Add to dashboard Cite

show abstract

“…Moreover, an increased use of neoadjuvant chemoradiotherapy significantly compromises prognostication of survival based on pathologic TNM staging. 16 Initial studies of the prognostic value of SUV max, , including both surgical and nonsurgical patients, were conflicting. Investigators from the Netherlands studied whether SUV can be used as a predictor of survival in 40 esophageal cancer patients including 19 who underwent esophagectomy.…”

Section: Discussionmentioning

confidence: 99%

Does the Value of PET-CT Extend Beyond Pretreatment Staging? An Analysis of Survival in Surgical Patients with Esophageal Cancer

Sepesi

Raymond

Polomsky

et al. 2009

Journal of Gastrointestinal Surgery

View full text Add to dashboard Cite

show abstract

“…The poor clinical outcomes observed in N0 patients after neoadjuvant therapy suggest that they initially had nodal involvement and were downstaged by eradication of lymph node disease. 13 Recently, having undergone combinedmodality treatments for advanced esophageal adenocarcinoma, recurrences have mainly been from hematogenous metastatic spread as seen in our patient. 12 It might be assumed that while he remained disease-free for quite a long time after the operation, the presence of metastatic disease in his lymph nodes at the time of surgery caused cutaneus metastasis by hematogenous/lymphangitic spread.…”

Section: Discussionmentioning

confidence: 68%

Esophageal Adenocarcinoma Presenting with Skin Metastase: Case Report

Yılmaz¹,

Alptekın²,

Şahin³

et al. 2012

Turkiye Klinikleri J Med Sci

View full text Add to dashboard Cite

sophageal cancer is among cancers with the highest mortality worldwide. It is the ninth most common malignancy and the sixth most frequent cause of cancer death in the world, constituting 7% of all gastrointestinal cancers.1 Patients with esophageal cancer usually present with either locally advanced disease or with already metastasized stage at the time of initial diagnosis. Most long-term outcome studies in esophageal cancer have focused on quality of life issues. Factors associated with improved survival following surgical resection of esophageal cancer include low tumor stage and enbloc resection, favorable tumor grade and absence of lymphatic invasion, and pathologic complete response to neoadjuvant therapy. Case ReportA AB BS ST TR RA AC CT T Esophageal cancer is among cancers with the highest mortality rate worldwide. The ninth most common malignancy and the sixth most frequent cause of cancer death is esophageal cancer in the world, constituting 7% of all gastrointestinal cancers. Cutaneous metastases of esophageal adenocarcinoma are very rare. Loco-regional disease recurrence has been dramatically reduced with the institution of multimodality treatment for esophageal adenocarcinoma in the recent years. Skin metastasis of internal cancer is rare. In this report, we presented a 55-year-old male with adenocarcinoma of the distal esophagus that was treated with surgical excision and adjuvant chemotherapy. After a disease free interval of fourteen months the patient presented with cutaneous metastatic disease.K Ke ey y W Wo or rd ds s: : Esophageal neoplasms; recurrence; neoplasm metastasis Ö ÖZ ZE ET T Özofagus kanseri yeryüzündeki en ölümcül kanserlerden birisidir. En sık gözlenen dokuzuncu, kanser ölümlerinin ise en sık altıncı nedeni tüm dünyada özofagus kanseridir; aynı zamanda tüm gastrointestinal kanserlerin %7'sini oluşturmaktadır. Özofagus adenokarsinomunun kutanöz metastazları çok nadiren görülür. Son yıllarda özofagus kanserinde kullanıma giren multimodalite tedavileri sayesinde lokorejyonel nükslerin sıklığı dramatik olarak azalmıştır. İnternal kanserlerin cilt metastazları nadirdir. Bu yazıda cerrahi eksizyon sonrası adjuvan kemoterapiyle tedavi edilen distal özofagus adenokarsinomlu 55 yaşında bir erkek olguyu sunuyoruz. Hastalıksız ondört aydan sonra hasta kutanöz metastatik hastalık nedeniyle yeniden başvurmuştur.A An na ah ht ta ar r K Ke el li im me el le er r: : Özofagus tümörleri; nüks; tümör metastazı T Tu ur rk ki iy ye e K Kl li in ni ik kl le er ri i J J M Me ed d S Sc ci i 2 20 01 12 2; ;3 32 2( (5 5)

show abstract

Survival in Lymph Node Negative Adenocarcinoma of the Esophagus after R0 Resection With and Without Neoadjuvant Therapy: Evidence for Downstaging of N Status

Cited by 18 publications

References 17 publications

Esophageal cancer—the five year survivors

Esophageal cancer—the five year survivors

Does the Value of PET-CT Extend Beyond Pretreatment Staging? An Analysis of Survival in Surgical Patients with Esophageal Cancer

Esophageal Adenocarcinoma Presenting with Skin Metastase: Case Report

Contact Info

Product

Resources

About